VR Logo

Clovis Oncology Inc. (CLVS) download report


Healthcare | Biotechnology & Pharma Research

Clovis Oncology Inc. (CLVS) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.

IPO Date: 16-Nov-2011

Co-Founder, CEO, Pres & Exec. Director: Mr. Patrick J. Mahaffy MA

Co-Founder, Exec. VP & Chief Regulatory Officer: Dr. Gillian C. Ivers-Read BSc

Listing: NASDAQ: CLVS

Country: United States

Headquarters: Boulder, CO

Website: https://www.clovisoncology.com

Key Facts

Market cap: $246.03 Mln

Revenue (TTM): $144.95 Mln

Earnings (TTM): $-258.42 Mln

Cash: $122.24 Mln

Total Debt: $437.28 Mln

Insider's Holding: 1.44%

Liquidity: Low

52 Week range: $0.58 - 5.92

Shares outstanding: 143,879,008

10 Years Aggregate:

  • CFO: $-2,173.19 Mln
  • EBITDA: $-2,597.29 Mln
  • Net Profit: $-2,769.11 Mln

Stock Performance

Time Period Clovis Oncology (CLVS) S&P BSE Sensex S&P Small-Cap 600
YTD-30.81-8.99-19.23
1 month171.74-3.40-9.35
3 months9.65-8.50-16.59
1 Year-67.950.89-17.36
3 Years-49.8510.415.90
5 Years-54.1011.435.77
10 Years-21.7111.779.78
As on 30-Jun-2022
Year Clovis Oncology (CLVS) S&P Small-Cap 600 S&P BSE Sensex
2021-43.5425.2721.99
2020-53.969.5715.75
2019-41.9520.8614.38
2018-73.40-9.705.87
201753.0811.7327.91
201626.9124.741.95
2015-37.50-3.36-5.03